Notable Labs (NTBLQ) AI Stock Analysis

• Market Cap: $10.00
• Dividend Yield: N/A
• Average Volume (3M): 30.25K
• Price to Earnings (P/E): ―
• Beta (1Y): -62.19
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 9,659,496
• 10 Day Avg. Volume: 43,656
• 30 Day Avg. Volume: 30,250
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -1.3
• Revenue Forecast (FY): $1.18M

No summary available

Positive Factors

Partnership Revenue Model

The company's revenue model, based on strategic partnerships, provides a scalable path to growth by leveraging external expertise and resources.

Negative Factors

Ongoing Losses

Persistent losses hinder the company's ability to reinvest in growth opportunities and may necessitate additional financing, impacting long-term sustainability.

Notable Labs Business Overview & Revenue Model

Company Description

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease...

Read more

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease...

How the Company Makes Money

Notable Labs generates revenue primarily through partnerships and collaborations with pharmaceutical companies and research institutions. The company offers its platform as a service to these partners, who use it to screen and identify promising d...

Read more

Notable Labs generates revenue primarily through partnerships and collaborations with pharmaceutical companies and research institutions. The company offers its platform as a service to these partners, who use it to screen and identify promising d...

Notable Labs Financial Statement Overview

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	―	―	―	―	―
Gross Profit	113.00K	8.00K	403.00K	528.00K	340.00K
EBITDA	-14.40M	-12.60M	-16.59M	-22.92M	-19.73M
Net Income	-11.26M	-14.41M	-16.05M	-24.23M	-21.14M
Balance Sheet
Total Assets	19.54M	5.51M	64.66M	41.70M	49.01M
Cash, Cash Equivalents and Short-Term Investments	―	―	―	―	―
Total Debt	2.05M	361.00K	2.35M	2.53M	2.94M
Total Liabilities	4.43M	7.13M	12.48M	10.79M	12.98M
Stockholders Equity	―	―	―	―	―
Cash Flow
Free Cash Flow	-13.78M	-11.59M	-26.45M	-23.42M	25.51M
Operating Cash Flow	-13.72M	-11.64M	-24.98M	-23.37M	25.58M
Investing Cash Flow	―	―	―	―	―
Financing Cash Flow	―	―	―	―	―

Notable Labs Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTBLQ, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.31 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NTBLQ.

Notable Labs Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NTBLQ	―	$10.00	―	―	―	―	―
DRMA	44 Neutral	$5.15M	-0.28	-203.36%	―	―	90.53%
AZTR	43 Neutral	$3.81M	-0.12	-215.04%	―	-100.00%	93.82%
ENVB	42 Neutral	$3.70M	-0.10	-262.78%	―	―	79.45%
REVB	42 Neutral	$4.50M	-2.23	-0.40%	―	―	96.26%